Skip to content

Biora Therapeutics, Inc.

CIK 0001580063

← back to feed
Revenue (TTM)
$892K
−71.4% YoY Q3 Nov 2024
Net Income (TTM)
−$89.58M
−804.5% YoY Q3 Nov 2024
EPS Diluted (TTM)
−$54.11
−379.9% YoY Q3 Nov 2024
Gross Margin
335.5%
Q3 Nov 2024
Operating Margin
-7,942.8%
Q3 Nov 2024
Net Margin
-10,042.6%
Q3 Nov 2024
Free Cash Flow (TTM)
−$97.91M
Q3 Nov 2024
Cash
$3M
Q3 Nov 2024
Total Debt
—
Q3 Nov 2024
Shares Outstanding
4.52M sh
Q3 Nov 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings